March 3, 2026Open Access

Real-world efficacy and prognostic factors of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China

Key Points

Real-world efficacy of CDK4/6 inhibitors shows favorable outcomes in HR+/HER2− metastatic breast cancer patients.
In this study, patients experienced significant benefits when using CDK4/6 inhibitors as a first-line treatment.
Retrospective analysis across multiple centers in central China highlights the role of clinical factors in treatment decisions.
Identifying prognostic factors could enhance treatment selection and risk stratification for better patient outcomes.

Abstract

CDK4/6i demonstrates favorable real-world efficacy in HR+/HER2- MBC patients in central China, particularly in the first-line setting. Several clinical factors may aid in treatment selection and risk stratification.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Liu et al. (Thu,) studied this question.

synapsesocial.com/papers/69a75d3cc6e9836116a26ee0 https://doi.org/https://doi.org/10.21037/tbcr-25-37

Bookmark

View Full Paper